Pregled bibliografske jedinice broj: 1035476
Extracellular ATP as a biomarker of severity of chronic obstructive pulmonary disease
Extracellular ATP as a biomarker of severity of chronic obstructive pulmonary disease // ERS International Congress 2019
Madrid, 2019. str. 188-188 (predavanje, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 1035476 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Extracellular ATP as a biomarker of severity of chronic obstructive pulmonary disease
Autori
Somborac Bačura, Anita ; Grdić Rajković, Marija ; Hulina Tomašković, Andrea ; Hlapčić, Iva ; Rogić, Dunja ; Popović-Grle, Sanja ; Rumora, Lada
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
ERS International Congress 2019
/ - Madrid, 2019, 188-188
Skup
ERS International Congress 2019
Mjesto i datum
Madrid, Španjolska, 28.09.2019. - 02.10.2019
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
COPD, extracellular ATP, EDTA plasma
Sažetak
Introduction: Cigarette smoking is the main etiologic factor for chronic obstructive pulmonary disease (COPD), characterized by chronic airway inflammation. Extracellular ATP (eATP) is a damage-associated molecular pattern (DAMP) molecule that may induce activation of inflammatory cells. Aims and objectives: The aim of this study was to assess eATP concentration in stable COPD patients in relation to the severity of the disease and smoking status. Methods: We obtained blood samples from stable COPD patients (N=137) and healthy volunteers (N=95), matched by age and sex. COPD patients were divided into subgroups according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) or "ABCD" classifications, by both mMRC (modified Medical Research Council) and CAT (COPD assessment test) questionnaires. Plasma eATP concentrations were determined using the commercially available luminescence assay. Nonparametric statistics using the MedCalc software was used for data analysis. Results: Plasma eATP concentration was significantly increased in COPD patients compared to healthy controls (P<0.001) and was also elevated in healthy smokers compared to healthy non-smokers (P<0.001). We found significant negative correlation between eATP and both FEV1 (r=-0.764) and FEV1/FVC (r=-0.661) in COPD patients, P<0.001. Moreover, plasma eATP concentration showed a severity of the disease-associated increase according to both GOLD and "ABCD" classifications (by mMRC and CAT questionnaires), P<0.001. Finally, eATP correlated with the number of exacerbations in COPD patients (r=0.505, P<0.001). Conclusions: Plasma eATP concentration might be a simple biomarker of severity and disease progression in COPD patients.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti, Farmacija
POVEZANOST RADA
Projekti:
HRZZ-IP-2014-09-1247 - Uloga stresnog proteina Hsp70 u imunosno-upalnom odgovoru kod kronične opstrukcijske plućne bolesti (Hsp70COPD) (HRZZ - 2014-09) ( CroRIS)
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
Klinika za plućne bolesti "Jordanovac",
Klinički bolnički centar Zagreb
Profili:
Marija Grdić Rajković
(autor)
Andrea Hulina Tomašković
(autor)
Lada Rumora
(autor)
Sanja Popović-Grle
(autor)
Anita Somborac Bačura
(autor)
Dunja Rogić
(autor)
Iva Hlapčić
(autor)